**Supplemental Table 3:**

The inhibition effects of standard antibiotics with control species by the CLSI (2019).

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Standard antibiotics** | **SA** **ATCC 25923** | **SA****ATCC 43300** | **KP\*****ATCC 700603** | **PA\*****ATCC 27853** |
| Piperacillin/tazobactam (100/10 µg)  | 28 | 25 | NT | 28 |
| Amikacin (30 µg) | 23 | 30 | 20 | 23 |
| Ceftriaxone (30 µg) | NT | NT | 18 | NT |
| Cefotaxime (30 µg) | NT | 25 | 17 | NT |
| Ceftazidime (30 x)  | 26 | NT | 13 | 26 |
| Ciprofloxacin (5 µg) | 30 | 30 | NT | 30 |
| Imipenem (10 µg) | 22 | NT | 29 | 22 |
| Trimethoprim/sulfamethoxazole (1.25/23.75µg) | NT | 30 | NT | NT |
| Vancomycin (30 µg) | NT | 18 | NT | NT |

**SA ATCC 25923**: *Staphylococcus aureus* ATCC 43300. **SA ATCC 43300**: *Staphylococcus aureus* ATCC 43300. **KP\* ATCC 700603**: *K. pneumoniae* ATCC 700603 and **PA\* ATCC 27853**: *Pseudomonas aeruginosa* ATCC 27853. These strains were used as control species; the inhibition zone in each antibiotic was within the quality control ranges set by the CLSI (2019)\*. NT abbreviation was refer to not tested.

\*The quality control ranges set by the CLSI (2019): For *K. pneumoniae* strain ATCC 700603, the different clear zone diameter of antibiotics including ceftazidime (10-18 mm), cefotaxime (17-25 mm), and ceftriaxone (16-24 mm). For *P. aeruginosa* strain ATCC 27853, the different clear zone diameter of antibiotics including piperacillin/tazobactam (25-33 mm), amikacin (18-26 mm), and ciprofloxacin (25-33 mm).